Third Quarter Revenue Growth of 39% to $139 Million
Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million
BRISBANE, Calif. — (BUSINESS WIRE) — CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Financial Highlights
• Revenue of $139 million, an increase of 39% year-over-year
• Testing Services revenue of $119 million, an increase of 65% year-over-year
• Testing Services volume of approximately 75,900, an increase of 51% year-over-year, including contributions following our acquisition of NavDx
• Patient and Digital Solutions revenue of $20 million, an increase of 31% year-over-year
• GAAP net income of $19 million, compared with GAAP net income of $2 million for the third quarter of 2025
• Closed the acquisition of Naveris, Inc.